Pharmacogenomics of hepatitis C infections: Personalizing therapy

Genome Medicine

Volumn 4, Issue 12, 2012, Pages

  Booth, David R ^a   Ahlenstiel, Golo ^a   George, Jacob ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA; RIBAVIRIN;

ANTIVIRAL THERAPY; DRUG RESPONSE; FLU LIKE SYNDROME; GENOTYPE; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENTAL DISEASE; MIXED INFECTION; NONHUMAN; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; VIRAL CLEARANCE;

EID: 84871111249     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm400     Document Type: Review

References (51)

1. Manolio TA. Genome-wide association studies and assessment of the risk of disease. N Engl J Med 2010, 363:166-176. 10.1056/NEJMra0905980, 20647212.
2. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401. 10.1038/nature08309, 19684573.
3. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41:1100-1104. 10.1038/ng.447, 19749758.
4. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41:1105-1109. 10.1038/ng.449, 19749757.
5. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY, . Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338-1345. 10.1053/j.gastro.2009.12.056, 20060832, Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study.
6. Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon SC, Marotta P, Vierling JM, Lopez-Talavera JC, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010, 52:822-832. 10.1002/hep.23743, 20564352.
7. World Health Organization (WHO) Hepatitis C. Fact Sheet No. 164. Revised July 2012 World Health Organization (WHO)., http://www.who.int/mediacentre/factsheets/fs164/en/
8. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006, 13:34-41. 10.1111/j.1365-2893.2005.00651.x, 16364080.
9. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002, 36:S21-S29.
10. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005, 9:383-398. 10.1016/j.cld.2005.05.003, 16023972.
11. Chu TW, Kulkarni R, Gane ED, Roberts SK, Stedman C, Angus P, Ritchia B, Lu XY, Ipe D, Lopatin U, Germer S, Iglesias VA, Elston R, Smith PF, Shulman NS. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 2012, 142:790-795. 10.1053/j.gastro.2011.12.057, 22248659.
12. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, . American Association for Study of Liver Diseases An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-1444. 10.1002/hep.24641, 3229841, 21898493, American Association for Study of Liver Diseases.
13. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, Rotman Y, Liang TJ. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012, 142:978-988. 10.1053/j.gastro.2011.12.055, 22248663.
14. Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, Luxon BA, Lemon SM, Lanford RE. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004, 78:13779-13792. 10.1128/JVI.78.24.13779-13792.2004, 533929, 15564486.
15. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, Heim MH. Interferon signalling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008, 105:7034-7039. 10.1073/pnas.0707882105, 2383932, 18467494.
16. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, Bukh J, Purcell RH, Schultz PG, Chisari FV. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 2002, 99:15669-15674. 10.1073/pnas.202608199, 137774, 12441396.
17. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801. 10.1038/nature08463, 3172006, 19759533.
18. Hertzog PJ. Overview. Type I interferons as primers, activators and inhibitors of innate and adaptive immune responses. Immunol Cell Biol 2012, 90:471-473. 10.1038/icb.2012.15, 22648073.
19. Fischer J, Böhm S, Scholz M, Müller T, Witt H, George J, Sarrazin C, Susser S, Schott E, Suppiah V, Booth DR, Stewart GJ, van Bömmel F, Brodzinski A, Fülöp B, Migaud P, Berg T. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 2012, 55:1700-1710. 10.1002/hep.25582, 22234924.
20. Smith KR, Suppiah V, O'Connor K, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Matthews G, Irving WL, Powell E, Riordan S, Ahlenstiel G, Stewart GJ, Bahlo M, George J, Booth DR, . the International Hepatitis C Genetics Consortium Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med 2011, 3:57. 10.1186/gm273, 3238183, 21884576, the International Hepatitis C Genetics Consortium.
21. Suppiah V, Gaudieri S, Armstrong N, O'Connor KS, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Dore GJ, Irving WL, Powell E, Hellard M, Riordan S, Matthews G, Sheridan D, Nattermann J, Smedile A, Muller T, Hammond E, Dunn D, Negro F, Bochud PY, Mallal S, Ahlenstiel G, Stewart GJ, George J, Booth DR, . for the International Hepatitis C Genetics Consortium IL28B, HLA-C and KIR variants additively and interactively predict response to therapy in chronic hepatitis C Virus infection. PLoS Med 2011, 8:e1001092. 10.1371/journal.pmed.1001092, 3172251, 21931540, for the International Hepatitis C Genetics Consortium.
22. Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR, Goldstein DB, . Pharmacogenetics and Hepatitis C Meeting Participants Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2011, 53:336-345. 10.1002/hep.24052, 21254181, Pharmacogenetics and Hepatitis C Meeting Participants.
23. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afdhal N. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010, 52:1888-1896. 10.1002/hep.23912, 20931559.
24. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, Papassotiropoulos A, Roth V, Heim MH. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011, 140:1021-1031. 10.1053/j.gastro.2010.11.039, 21111740.
25. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shirasaki T, Horimoto K, Tanaka Y, Tokunaga K, Mizokami M, Kaneko S, . Hokuriku Liver Study Group Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010, 139:499-509. 10.1053/j.gastro.2010.04.049, 20434452, Hokuriku Liver Study Group.
26. Sugiyama M, Tanaka Y, Wakita T, Nakanishi M, Mizokami M. Genetic variation of the IL-28B promoter affecting gene expression. PLoS One 2011, 6:e26620. 10.1371/journal.pone.0026620, 3201970, 22046316.
27. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010, 14:1-21. 10.1016/j.cld.2009.11.009, 20123436.
28. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567. 10.1016/S1473-3099(05)70216-4, 16122679.
29. Hayes CN, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Imamura M, Ochi H, Kamatani N, Nakamura Y, Chayama K. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 2011, 60:261-267. 10.1136/gut.2010.223495, 21068134.
30. Schreiber J, Moreno C, Garcia BG, Louvet A, Trepo E, Henrion J, Thabut D, Mathurin P, Deltenre P. Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients. Aliment Pharmacol Ther 2012, 36:353-362. 10.1111/j.1365-2036.2012.05197.x, 22742526.
31. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010, 139:821-827. 10.1053/j.gastro.2010.05.079, 20621700.
32. De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, Soffredini R, De Francesco R, Prati GM, D'Ambrosio R, Cheroni C, Donato MF, Colombo M. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 2012, 55:336-342. 10.1002/hep.24683, 21932415.
33. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139:120-129. 10.1053/j.gastro.2010.04.013, 20399780.
34. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Copetti M, Minerva N, Petruzzellis D, Mottola L, Bacca D, McHutchison JG. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology 2011, 54:772-780. 10.1002/hep.24458, 21626525.
35. Nattermann J, Timm J, Nischalke HD, Olbrich A, Michalk M, Tillmann HL, Berg T, Wedemeyer H, Tenckhoff H, Wiese M, Kullig U, Göbel U, Capka E, Schiefke I, Güthof W, Grüngreiff K, König I, Roggendorf M, Sauerbruch T, Spengler U, . East German HCV Study Group The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Δ32 mutation. J Hepatol 2011, 55:1201-1206. 10.1016/j.jhep.2011.03.011, 21703201, East German HCV Study Group.
36. O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML, Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM, . HALT-C Trial Group An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One 2011, 6:e20904. 10.1371/journal.pone.0020904, 3132753, 21760886, HALT-C Trial Group.
37. Lagging M, Askarieh G, Negro F, Bibert S, Söderholm J, Westin J, Lindh M, Romero A, Missale G, Ferrari C, Neumann AU, Pawlotsky JM, Haagmans BL, Zeuzem S, Bochud PY, Hellstrand K, . DITTO-HCV Study Group Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 2011, 6:e17232. 10.1371/journal.pone.0017232, 3044738, 21390311, DITTO-HCV Study Group.
38. Falleti E, Bitetto D, Fabris C, Fattovich G, Cussigh A, Cmet S, Ceriani E, Fornasiere E, Pasino M, Ieluzzi D, Pirisi M, Toniutto P. Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Hepatology 2012, 56:1641-1650. 10.1002/hep.25848, 22610885.
39. Clausen LN, Astvad K, Ladelund S, Larsen MV, Schønning K, Benfield T. Hepatitis C viral load, genotype 3 and interleukin-28B CC genotype predict mortality in HIV and hepatitis C-coinfected individuals. AIDS 2012, 26:1509-1516. 10.1097/QAD.0b013e3283553581, 22555162.
40. Parczewski M, Bander D, Leszczyszyn-Pynka M, Urbańska A, Socha L, Boroń-Kaczmarska A. IL28B CC genotype is associated with higher all-cause mortality in antiretroviral-treated HIV-infected patients. AIDS Res Hum Retroviruses 2012, 28:1640-1646. 10.1089/aid.2011.0354, 22545770.
41. Vispo E, Rallon NI, Labarga P, Barreiro P, Benito JM, Soriano V. Different impact of IL28B polymorphisms on response to peginterferon-á plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. J Clin Virol 2012, 55:58-61. 10.1016/j.jcv.2012.05.012, 22727259.
42. Dayyeh BK, Gupta N, Sherman KE, de Bakker PI, Chung RT. Aids Clinical Trials Group A5178 Study Team. IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy. PLoS One 2011, 6:e25753. 10.1371/journal.pone.0025753, 3189209, 22003405.
43. Tanaka Y, Kurosaki M, Nishida N, Sugiyama M, Matsuura K, Sakamoto N, Enomoto N, Yatsuhashi H, Nishiguchi S, Hino K, Hige S, Itoh Y, Tanaka E, Mochida S, Honda M, Hiasa Y, Koike A, Sugauchi F, Kaneko S, Izumi N, Tokunaga K, Mizokami M. Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum Mol Genet 2011, 20:3507-3516. 10.1093/hmg/ddr249, 21659334.
44. Thompson AJ, Clark PJ, Singh A, Ge D, Fellay J, Zhu M, Zhu Q, Urban TJ, Patel K, Tillmann HL, Naggie S, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, King JW, Kwo PY, Shianna KV, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, Goldstein DB, McHutchison JG, Muir AJ. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol 2012, 56:313-319. 10.1016/j.jhep.2011.04.021, 21703177.
45. Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, Buchbinder S, Carrington M, Thio CL. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 2010, 202:1749-1753. 10.1086/657146, 2974014,2974014, 20977343.
46. Peng LJ, Guo JS, Zhang Z, Shi H, Wang J, Wang JY. IL28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection. Tissue Antigens 2012, 79:302-305. 10.1111/j.1399-0039.2011.01835.x, 22239156.
47. Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Buster EH, Uitterlinden AG, Hansen BE, Chan HL, Janssen HL. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012, 142:513-520. 10.1053/j.gastro.2011.11.025, 22108195.
48. Wu X, Xin Z, Zhu X, Pan L, Li Z, Li H, Liu Y. Evaluation of susceptibility locus for response to interferon-á based therapy in chronic hepatitis B patients in Chinese. Antiviral Res 2012, 93:297-300. 10.1016/j.antiviral.2011.12.009, 22209781.
49. Poordad F, Bronowicki J, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Burroughs M, Sniukiene V, Boparai N, Brass CA, Albrecht JK, Bacon BR. IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with Boceprevir combination. Hepatology 2011, 54(Suppl 1):S6..
50. Jacobson IM, Catlett I, Marcellin P, Bzowej NH, Muir AJ, Adda N, Bengtsson L, George S, Seepersaud S, Ramachandran R, Sussky K, Kauffman RS, Botfield M. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. J Hepatol 2011, 54(Suppl 1):S542-S543.
51. Thompson AJ, McHutchison JG. Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?. Hepatology 2012, 56:373-381. 10.1002/hep.25792, 22511355.